Bacilligen is a biotechnology company focusing on the development of cancer and infectious disease vaccines and therapeutics. Bacilligenâs lead product is an improved bladder cancer therapy based on rMB, propriety recombinant mycobacteria. Bacilligenâs other product candidates, which include vaccines for AIDS, cancer, and influenza, are based on a novel bacteriophage capsid system, BVS, for the delivery of nucleic acid therapies and vaccines for cancer and infectious disease. Bacilligenâs BVS possesses speed and efficiency/cost advantages that make it the system of choice for rapid development and production of custom biological therapies and vaccines, including in personalized medicine and emergency preparedness set
